- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Fox Outlines Management Challenges in Multiple Myeloma
John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, discusses management challenges still facing providers treating multiple myeloma.
John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health, discusses management challenges still facing providers treating multiple myeloma.
Transcript
While the multiple myeloma treatment landscape has improved, what are the biggest management challenges providers treating the diseases still face?
In the las half a decade, there have been 5 or 6 drugs that have been approved for multiple myeloma and even more combinations of drugs, and in this day and era, we have more and more options available to patients, but we don’t understand how to best use those options. We need more information about the role of transplant is, especially in an era where we have very high MRD [minimal residual disease]- negativity.
We need more information about the duration of treatment, especially when you’re MRD negative, because these drugs could be used for the rest of one’s life, and if there’s no added value and there’s accumulated toxicity or increased risk of cardiopulmonary toxicity or increased risk of cancer, patients need to weigh those and physicians need to weigh those. In the absence of information, how long do you treat patients? We’re operating in the dark. So, I think those are some of the areas: what’s the role of transplant, what’s the role of multiple drug combinations, the relative benefits, and then how long do we need to treat people who have a very good response?
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation
April 10th 2025Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Read More
